EUVIMEDEUVIMED entdecken
Crossref

‘Folfirinox’ chemotherapy combined with contact x-ray brachytherapy 50 kVp and ‘CAP50’ chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study

D Mitrea, N Barbet, T Pacé-Loscos, C Scouarnec, S Ben-Dhia, D Baron, L Mineur, L Évesque, J Durand-Labrunie, J-P Gérard, G Baudin, J Doyen

Cancer/Radiothérapie · 2024

DOI: 10.1016/j.canrad.2024.02.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer/Radiothérapie, 2024. Verfasst von D Mitrea und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre Antoine-Lacassagne, Nice, France. Electronic address: diana.mitrea@nice.unicancer.fr. Hauptthemen laut MEDLINE: Rectal Neoplasms, Feasibility Studies, Brachytherapy, Fluorouracil. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The standard treatment of T2-T3 rectal adenocarcinoma is radical proctectomy by total mesorectal excision often combined with some neoadjuvant treatment. To reduce morbidity of this surgery, organ preservation strategy using various combination of radiotherapy, chemotherapy and local excision is gaining interest. Some randomized trials have proven the feasibility of such approaches. The OPERA trial demonstrated, for T2 T3

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsFeasibility StudiesBrachytherapyFluorouracilChemoradiotherapyAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsOxaliplatinCapecitabineNeoadjuvant TherapyIrinotecanHumansAgedFemaleMaleLeucovorinOrgan Sparing TreatmentsNeoplasm Staging

Stichwörter der Autor:innen

ContactherapyContactthérapieFolfirinoxPreTresorPréTresorPréservation rectaleRectal preservation

Substanzen

FluorouracilOxaliplatinCapecitabinefolfirinoxIrinotecanLeucovorin

Autor:innen und Institutionen

  • Centre Antoine-Lacassagne, Nice, France. Electronic address: diana.mitrea@nice.unicancer.fr.
  • Centre Bayard Orlam, Villeurbanne, France.
  • Centre Antoine-Lacassagne, Nice, France.
  • Institut Sainte-Catherine, Avignon, France.
  • Institut Gustave-Roussy, Villejuif, France.

Zitieren

APA

Mitrea, D., Barbet, N., Pacé-Loscos, T., Scouarnec, C., Ben-Dhia, S., Baron, D., Mineur, L., Évesque, L., Durand-Labrunie, J., Gérard, J. P., Baudin, G., & Doyen, J. (2024). ‘Folfirinox’ chemotherapy combined with contact x-ray brachytherapy 50 kVp and ‘CAP50’ chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study. Cancer/Radiothérapie. https://doi.org/10.1016/j.canrad.2024.02.003

Vancouver

Mitrea D, Barbet N, Pacé-Loscos T, Scouarnec C, Ben-Dhia S, Baron D, et al. ‘Folfirinox’ chemotherapy combined with contact x-ray brachytherapy 50 kVp and ‘CAP50’ chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study. Cancer/Radiothérapie. 2024. doi:10.1016/j.canrad.2024.02.003

BibTeX
@article{Mitrea2024,
  author = {Mitrea, D and Barbet, N and Pacé-Loscos, T and Scouarnec, C and Ben-Dhia, S and Baron, D and Mineur, L and Évesque, L and Durand-Labrunie, J and Gérard, J-P and Baudin, G and Doyen, J},
  title = {‘Folfirinox’ chemotherapy combined with contact x-ray brachytherapy 50 kVp and ‘CAP50’ chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study},
  journal = {Cancer/Radiothérapie},
  year = {2024},
  doi = {10.1016/j.canrad.2024.02.003}
}
Kostenlos starten →